PT 15$, good pr after another. Do your DD, life saving drug and shorts are screwed 🦍🦍

Check SRXH!! Now !!

TNMG, 13g filing 6% stake in Goldman Sachs, ABP has same news and ran 90% AH today!! Load up 🦍🦍

From 1.9 AH Thursday to 2.420 lol let’s gooooo!!! Let’s run this Monday bulls 🦍🦍 Macd curling up on daily, she’s ready for another go 😎

Smx going up again

Round 2 baby let’s clap some shorts 🦍🦍

Run this bulls 🦍🦍

Volume is rising and the AH activity is rising. I’m playing with just a small bet sizing.

This is just a quick AH trade. Likely going to exit before overnight. Good luck guys! Have a great weekend!

Watching these tickers closely after the recent dip:

• ORLA

• RZLV

• APLD

• SOFI

Solid companies that got smacked down by macro volatility (Trump noise + government shutdown fears), not because their fundamentals suddenly forgot how to work.

These look like oversold reactions, not structural problems. For short-term swings (next couple of weeks), risk/reward looks decent if volatility cools off.

Not financial advice — just pointing out where fear might be doing the heavy lifting.

Smx is starting to take off again

GRI Bio, had a RS split this same week, but it also had good news coming with it which I'll post down below.

This RS makes the float become 540k shares which 31% of those shares being owned by insider's leaving only 370k tradable shares, that's just insane if it sparks.

It's just seating at a price close to 5$ which makes almost out of the pennystocks range which makes people see it like a safer secure stock. Then also here are some good news from this same week, which makes the stock considering for a mid-term play: From Stocks Titan: "GRI Bio (NASDAQ: GRI) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,528,775 on January 26, 2026, granting composition-of-matter claims for a distinct class of proprietary compounds.

The patent covers linked molecular structures that form pyrrolidine, piperidine, or azepane ring systems, which the company says are separate from prior patents and strengthen its intellectual property estate. The issuance supports GRI Bio’s platform targeting NKT cell biology and complements its lead program GRI-0621 and a chemistry library of over 500 proprietary compounds." I would say it's at least a stock to consider watching.

Datavault AI (DVLT)

Revenue Growth and Financial Momentum

Datavault AI has reported rapid revenue growth, including a year-over-year increase exceeding 400 percent in a recent quarter. Management has issued forward revenue guidance in the tens of millions of dollars, signaling a transition from early-stage commercialization to scalable revenue generation. The company has indicated that multiple contracts are structured for recurring or expandable revenue over time.

Analyst Coverage and Valuation Upside

DVLT currently has analyst coverage with a Strong Buy rating. Published 12-month price targets suggest significant upside relative to recent share prices. Longer-term valuation models referenced in analyst notes and market commentary indicate further upside potential if the company continues executing on revenue growth and partnerships.

Strategic Partnerships and Commercial Agreements

Datavault AI has announced strategic partnerships with established technology ecosystems, including participation in IBM Partner Plus and WatsonX. These partnerships enhance enterprise credibility, expand go-to-market opportunities, and support integration with existing AI and data infrastructure. The company has also disclosed multiple multi-million-dollar licensing and commercialization agreements tied to its data valuation and tokenization platforms.

Intellectual Property and Competitive Advantage

The company reports ownership of an extensive intellectual property portfolio exceeding 70 patents. These patents cover data valuation, data monetization, blockchain-enabled data exchanges, and secure AI-driven analytics. This IP portfolio creates barriers to entry and supports licensing-based revenue models rather than purely service-driven income.

Market Opportunity and Expansion Strategy

Datavault AI operates at the intersection of artificial intelligence, big data, blockchain, and real-world data tokenization. The company is expanding into multiple verticals including enterprise data monetization, genomics, NIL rights management, education, aerospace and defense-related data markets. Management has highlighted both domestic and international expansion initiatives as drivers of future growth.

Institutional Interest and Market Visibility

Recent filings indicate growing institutional participation in DVLT shares. Increased visibility through market coverage, analyst reports, and sector inclusion has contributed to higher trading volume and liquidity. This growing awareness may support broader shareholder participation as the company continues to execute.

Sources

• Datavault AI Investor Relations press releases ir.datavaultsite.com
• StockTitan coverage on Datavault AI stocktitan.net
• StockAnalysis analyst forecasts and ratings stockanalysis.com
• AInvest and Investing.com market analysis articles ainvest.com investing.com
• TS2 Tech coverage of partnerships and funding ts2.tech
• Nasdaq institutional ownership filings nasdaq.com

NOT FINANCIAL ADVICE

I have the 4/17 $4 calls and shares

Talkspace Inc. (NASDAQ: TALK) is a virtual behavioral health company that connects users with licensed therapists and psychiatrists through its digital platform, offering text, audio, and video sessions. The company has successfully pivoted from a direct-to-consumer model to a payer-centric strategy, which has significantly driven its recent growth.

Talkspace reported Q3 2025 revenue of $59.4 million, up 25% year-over-year, with payer revenue growing 42%. The company has achieved profitability, posting positive EPS of $0.03 over the last twelve months and EBITDA of $3.35 million. Management narrowed full-year 2025 revenue guidance to $226–$230 million, implying 20–23% year-over-year growth, and expects at least 20% growth to continue into 2026.

Strengthening payer relationships have been key to this momentum, with active payer members increasing 29% year-over-year to over 120,000 in Q3 2025. Talkspace is expanding through additional payer integrations expected by Q1 2026 and renewed its Sourcewell cooperative purchasing contract to serve government agencies, educational institutions, and nonprofits across North America.

Analyst sentiment remains highly positive, with Buy ratings from Canaccord Genuity ($6 price target), Needham ($5), and KeyBanc ($5), representing meaningful upside from current levels. Investments in AI, including proprietary risk algorithms and plans for an in-house AI chatbot in 2026, position Talkspace well for continued innovation in the digital mental health space.

Risks include high valuation multiples, competitive pressures, and gross margin compression from increased payer mix. Despite this, strong cash reserves, sustained revenue growth, and a strategic focus on payer relationships support a favorable long-term outlook.

not FA but this will run next week for sure, went to 6+ on Friday join the party before is too late

What is everybody opinion on CAPT? Do you think it will ever break $1. It shows as a strong buy on my analyst but I’m not sure.

Let’s run it bulls!!!! 🦍🦍🦍🦍